Featured Story

Charles River Closes $380m HemaCare Cell Therapy Takeover


In November 2019, Charles River singled out cell and gene therapies as the fastest growing component of its biologics business. The following month, the big preclinical contract research organization (CRO) revealed a $380m deal to buy HemaCare.

Read the Full Article